Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MT10109L (NivobotulinumtoxinA) for Lateral Canthal Lines
NCT03785145Phase 3Completed
- Sponsor
- Medytox Inc.
- Start
- Dec 2018
- Primary completion
- Feb 2020
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 3
01
Overview
A Phase 3 trial of nivolumab + botulinumtoxinA in lateral canthal rhytides, sponsored by Medytox Inc.. Started Dec 2018; status: completed.
02
Drugs
nivolumab + botulinumtoxinA
03
Conditions
lateral canthal rhytides
Beyond the preview
Go deeper on NCT03785145.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03785145.